← Back to Clinical Trials
Recruiting NCT06449664

NCT06449664 Training for Men Undergoing Androgen Deprivation Therapy.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06449664
Status Recruiting
Phase
Sponsor The Swedish School of Sport and Health Sciences
Condition Prostate Cancer
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-05-01
Primary Completion 2026-12

Eligibility & Interventions

Sex Male only
Min Age 50 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
ADT-train

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-05-01 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT). The main questions it aims to answer are: * How feasible and safe is the new training concept? * How efficient is the training concept to counteract side effects caused by ADT? Researchers will compare the new training concept with usual care to evaluate how efficient the training concept is to counteract the ADT-related side effects. Participants in the intervention group will perform the new training concept twice weekly for 12 weeks. Participants in the control group will only receive usual care. All participants will visit the laboratory at baseline and after 6 and 12 weeks to measure the primary and secondary outcomes.

Eligibility Criteria

Inclusion Criteria: 1. signed informed consent 2. histologically confirmed localised or locally advanced prostate cancer 3. planned radiotherapy in combination with ADT for at least six months (unfavorable intermediate risk and high-risk prostate cancer) with curative intent and with no known metastasis. Exclusion Criteria: 1. very high risk localised prostate cancer planned for radiotherapy and ADT plus abiraterone and cortisone 2. localized prostate cancer planned for radiotherapy without ADT 3. on-going or previously treated with ADT or other hormonal treatments 4. have any contraindications to physical testing/exercise as per the ACSM guidelines 5. unable to comply with study procedures

Contact & Investigator

Central Contact

Niklas Psilander, PhD

✉ niklas.psilander@gih.se

📞 +46 8 120 538 23

Frequently Asked Questions

Who can join the NCT06449664 clinical trial?

This trial is open to male participants only, aged 50 Years or older, up to 80 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06449664 currently recruiting?

Yes, NCT06449664 is actively recruiting participants. Contact the research team at niklas.psilander@gih.se for enrollment information.

Where is the NCT06449664 trial being conducted?

This trial is being conducted at Stockholm, Sweden.

Who is sponsoring the NCT06449664 clinical trial?

NCT06449664 is sponsored by The Swedish School of Sport and Health Sciences. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology